Harbour Capital Advisors’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Harbour Capital Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-11,835	Closed	-$380K	–	543
2017 Q1	$380K	Buy	+11,835	New	+$404K	0.17%	154
2016 Q4	–	Sell	-13,110	Closed	-$603K	–	242
2016 Q3	$603K	Buy	13,110 +5,250	+67%	+$274K	0.38%	98
2016 Q2	$395K	Buy	+7,860	New	+$418K	0.22%	152

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $33B AUM 40.62% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Harbour Capital Advisors's TEVA Position: Q2 2017 in Review

Harbour Capital Advisors sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q2 2017, closing a stake of 11,835 shares — an estimated $380K sold.

Harbour Capital Advisors first reported a position in TEVA in Q2 2016 and held it in 3 quarters. The position peaked at $603K in Q3 2016. 650 funds tracked by Wall St. Rank hold TEVA as of Q2 2017.

Harbour Capital Advisors reported no remaining Teva Pharmaceutical Industries Limited position as of Q2 2017 after selling out during the quarter.
Harbour Capital Advisors sold 11,835 Teva Pharmaceutical Industries Limited shares in Q2 2017, an estimated $380K.
Harbour Capital Advisors first reported a position in Teva Pharmaceutical Industries Limited in Q2 2016 and held it in 3 quarters.
Harbour Capital Advisors's Teva Pharmaceutical Industries Limited position peaked at $603K in Q3 2016.
650 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q2 2017.

Based on Harbour Capital Advisors's 13F filing for Q2 2017, filed 27 Jul 2017.